Sangamo Biosciences (NASDAQ: SGMO) reported Q1 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $3.94 million versus the consensus estimate of $5.49 million.

GUIDANCE:

Sangamo Biosciences sees FY2016 revenue of $20-25 million, versus the consensus of $22.76 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.